Modulation of RAS expression in human malignant cells by dietary supplements

Nutrition

Volumn 13, Issue 10, 1997, Pages 921-923

  Lewis, Kriste A ^a   Hohl, Raymond J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOHEXENE DERIVATIVE; LIMONENE; OMEGA 3 FATTY ACID; PERILLYL ALCOHOL; TERPENE;

CHEMISTRY; DIET SUPPLEMENTATION; EDITORIAL; GARLIC; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MEDICINAL PLANT; NEOPLASM; ONCOGENE RAS; TEA;

ANTINEOPLASTIC AGENTS; CYCLOHEXENES; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; GARLIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MONOTERPENES; NEOPLASMS; PLANTS, MEDICINAL; TEA; TERPENES;

EID: 0031242606     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(97)00261-X     Document Type: Note

References (32)

1. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 1992;18:1
2. Elegbede JA, Elson CE, Qureshi A, Tanner MA, Gould MN. Inhibition of DMBA-induced mammary cancer by the monoterpene d-limonene. Carcinogenesis 1984;5:661
3. Elgebede JA, Elson CE, Tanner MA, Qureshi A, Gould MN. Regression of rat primary mammary tumors following dietary d-limonene. J Natl Cancer Inst 1986;76:323
4. Maltzman TH, Hurt LM, Elson CE, Tanner MA, Gould MN. The prevention of nitrosomethylurea-induced mammary tumors by d-limonene and orange oil. Carcinogenesis 1989;10:781
5. Crowell PL, Ren Z, Lin S, Vedejs E, Gould MN. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 1994;47:1405
6. Haag JD, Gould MN. Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 1994;34:477
7. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682
8. Barbacid M. RAS genes. Annu Rev Biochem 1987;56:779
9. Lowry DR, Willumsen BM. Function and regulation of RAS. Annu Rev Biochem 1993;62:851
10. Chang EH, Furth ME, Scolnick EM, Lowry DR. Tumorigenic transformation of mammalian cells induced by a normal gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 1982;297:479
11. Denko NC, Giaccia AJ, Stringer JR, Stambrook PJ. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci USA 1994;91:1524
12. Feramisco JR, Clark R, Wong G, et al. Transient reversion of ras oncogene-induced transformation by antibodies specific for amino acid 12 of ras protein. Nature 1985;314:639
13. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989;57:1167
14. Schafer WR, Kim R, Sterne R, et al. Genetic and pharmacologic suppression of oncogenic mutations in RAS genes of yeast and humans. Science 1989;245:379
15. Sinensky M, Beck KA, Leonard S, Evans R. Differential effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 1990;265:19937
16. Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 1995;270:17508
17. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24
18. Thibault A, Samid D, Thompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483
19. Hohl RJ, Lewis K, Knapp H. Plasma lovastatin bioactivity, plasma cholesterol, and mevalonic acid excretion after high dose lovastatin therapy in humans. J Investig Med 1995;43:296A
20. ras farnsyl;protein transferase by CYS-AAX tetrapeptides. Cell 1990;62:81
21. Kohl N, Mosser S, deSolms S, et al. Selective inhibition of ras-dependent transformation by a farnesyl transferase inhibitor. Science 1993;260:1934
22. James G, Goldstein J, Brown M, et al. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science 1993;260:1937
23. Garcia AM, Rowell C, Ackerman K, Kowalczyk JJ, Lewis MD. Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J Biol Chem 1993;268:18415
24. 2X peptidomimetics. J Biol Chem 1993;268:20695
25. Hohl RJ, Lewis-Tibesar K, Pogatchnik DM, Weimer DF. Inhibition of RAS farnesylation by isoprenoid phosphonic acids. Clin Pharmacol Ther 1996;59:198
26. Singh SB, Zink DL, Bills GF, et al. Cylindrol A: a novel inhibitor of Ras farnesyl-protein transferase from Cylindrocarpon lucidum. Tetrahedron Lett 1995;36:4935
27. Crowell PL, Chang RR, Ren Z, Elson CE, Gould MN. Selective inhibition of isoprenylation of 21-26 kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 1991;266:17679
28. Gelb MH, Tamanoi F, Yokoyama K, et al. The inhibition of protein prenyltransferase by oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett 1995;91:169
29. Hohl RJ. Monoterpenes as regulators of malignant cell proliferation. Dietary pytochemicah in cancer prevention and treatment. New York: Plenum Press, 1996:137
30. H-ras processing. Biochem Biophys Res Commun 1996;225:660
31. Singh J, Hamid R, Reddy BS. Dietary fat and colon cancer: modulating effect of types and amount of dietary fat on ras-p21 function during promotion and progression stages of colon cancer. Cancer Res 1997;57:253
32. Agarwal R, Mukhtar H. Cancer chemoprevention by polyphenols in green tea and artichoke. Adv Exp Med Biol 1996;410:35